| RSS
Business center
Office
Post trade leads
Post
Rank promotion
Ranking
 
You are at: Home » News » International »

Phase III data on Novartis' Cosentyx in ankylosing spondylitis published in NEJM

Increase font size  Decrease font size Date:2015-12-25   Views:378

Novartis announced Wednesday that Phase III data published in the NEJM demonstrate that its IL-17A antagonist Cosentyx (secukinumab) resulted in significant clinical improvements versus placebo at reducing the signs and symptoms of active ankylosing spondylitis (AS). Atul Deodhar, an investigator in the Cosentyx clinical trial programme, said the findings "[add] to our growing understanding of the key role IL-17 plays in the pathophysiology of the disease."

 
 
[ Search ]  [ ]  [ Email ]  [ Print ]  [ Close ]  [ Top ]

 
Total:0comment(s) [View All]  Related comment

 
Recomment
Popular
 
 
Home | About | Service | copyright | agreement | contact | about | SiteMap | Links | GuestBook | Ads service | 京ICP 68975478-1
Tel:+86-10-68645975           Fax:+86-10-68645973
E-mail:yaoshang68@163.com     QQ:1483838028